32results about How to "Quite active" patented technology

The invention relates to the field of biological medicine, in particular to an application of Rakicidins compounds in resistance to clinical pathogenic anaerobic bacteria. Pharmacodynamic experiments indicate that the Rakicidins compounds have good resistant effect on the clinical pathogenic anaerobic bacteria and have the resistant effect on vancomycin enterococcus infection diseases. The Rakicidins compounds can be used for treating diarrhea, enteritis, alimentary infection, oral infection or skin acne caused by clostridium difficile as well as diseases such as urinary tract infection, or skin soft-tissue infection and the like.

The present invention relates to a novel purpose of hederagenin and a derivative of the hederagenin. An anti-depression test of the hederagenin and the derivative of the hederagenin shows obvious anti-depression activity, wherein, the salt derivative of the hederagenin has stronger anti-depression activity than the hederagenin; the hederagenin has stronger anti-depression activity than hederangenoside; the activities of the hederagenin and a hypericum extract are equivalent; sodium hederagenin has higher activity than the hypericum extract. The present invention has obvious pharmacological effect and stable quality; the raw material of the present invention has abundant source and cheap price and is safe with low toxin; the present invention has simple preparation technology and high yield, which provides novel medicine source for preventing, diagnosing, examining, protecting, remedying and researching on the depression and diseases directly related to the depression, is fit for the industrialization production, is easy for popularizing and applying and has very important value for developing and using Chinese officinal plant resource. Affective mental disorder is listed at top in Chinese disease general burden, and the research and manufacture of the drug for preventing and remedying the depression has obvious social benefit and economic benefit.

The invention belongs to the technical field of hydrocarbon steam-reforming hydrogen production, relates to a low-cost hydrocarbon steam-reforming catalyst and a preparation method thereof. According to the preparation method, waste nickel hydrocarbon steam-reforming catalysts are utilized for preparing a novel catalyst in a low cost manner, recycled waste catalysts are preprocessed, all the catalysts accordant with the requirements can be recycled by utilizing a coprecipitation-wet mixing method, and a NiO / CaO-Al2O3 type catalyst is prepared after the catalysts are subjected to steam curing after-treatment and is suitable for high-class hydrocarbon steam-reforming hydrogen production; the use effect of the recycled the waste catalysts is remarkable, more than 95% of catalysts accordant with the requirements can be recycled, then 10-20% of production cost can be lowered, not only can waste catalysts be effectively recycled, the preparation cost of the catalyst is lowered, but also the environmental pollution caused by waste residues can be eliminated, the physical and chemical properties, activity and activity stability of the catalyst are similar to the physical and chemical properties, activity and activity stability of the catalyst prepared by utilizing a conventional method, and the preparation method is simple and feasible and is easy to implement.

The invention discloses camphoryl pyrimidines, and a preparation method and an anti-tumor activity study thereof. With camphor as a raw material and under an alkaline catalysis condition, a series ofalpha,beta-unsaturated ketones are obtained through aldol condensation reaction of camphor with different aromatic aldehydes respectively, a series of camphoryl pyrimidines are obtained through annulation reaction of alpha,beta-unsaturated ketones with guanidine hydrochloride through catalysis of potassium tert-butoxide, and the anti-tumor activity of the synthesized camphoryl pyrimidines is studied. Experiments show that the camphoryl pyrimidines have good inhibitory activity on human multiple myeloma cells (RPMI-8226), human breast cancer cells (MDA-MB-231) and human non-small cell lung cancer cells (A549), have less toxicity on normal cell human gastric mucosa cells (GES-1), and have potential anti-tumor application value.

The invention relate to acyloxy containing hydroxyalkyl polysiloxane and a preparation method. The preparation method comprises steps as follows: hydrogen containing polysiloxane and a hydroxyalkyl acrylate or hydroxyalkyl methacrylate compound are taken as raw materials, a polymerization inhibitor is added, and a target product of acyloxy containing hydroxyalkyl polysiloxane is generated through the hydrosilylation reaction of silicon-hydrogen bonds and unsaturated double bonds under the action of a platinum catalyst at the reaction temperature of 80-145 DEG C; after the reaction, the unreacted hydroxyalkyl acrylate or hydroxyalkyl methacrylate compound is washed and removed with water, water and a solvent are removed through reduced pressure distillation, the polymerization inhibitor is removed through filtering, and the target product of acyloxy containing hydroxyalkyl polysiloxane is obtained. Acyloxy containing hydroxyalkyl polysiloxane prepared with the method contains active terminated hydroxyalkyl, and when acyloxy containing hydroxyalkyl polysiloxane is applied to preparation of high polymer materials such as modified polyacrylate and the like, the functional performance of modified siloxane-acrylate copolymers is improved.

The invention provides a regeneration method for a palladium catalyst. According to the regeneration method, the palladium catalyst with the activity incapable of meeting the production requirements after being treated with the existing regeneration method can meet the requirement for activity or higher activity required by production. The regeneration method includes the following steps that 1, impurities are in a palladium catalyst needed to be regenerated are removed; 2, the palladium catalyst which is subjected to impurity removing is reacted with a sodium chlorate solution and hydrochloric acid; 3, the pH value of a solution reacted in the step 2 is adjusted to be 4 or above, and drying is carried out; 4, a sample dried in the step 3 is roasted.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of soybean gene promoters pEIF1 and pEIF1-I in soybean, arabidopsis thaliana and tobacco. According to the invention, a gene RPS28 and a gene EIF1 are cloned from soybeans; a promoter pEIF1 and a promoter pEIF1-I are obtained through a CTAB method, then a soybean stable transformation vector is constructed, expression of pEIF1 and pEIF1-I driven GUS protein in all stages of soybean genetic transformation is achieved, it is found that pEIF1 and pEIF1-I driven GUS is expressed in cotyledons, radicles, germs, true leaves, compound leaves, buds, petioles, internodes, roots and root nodules, it is indicated that pEIF1 and pEIF1-I are pan-expression promoters, and the activity of the expression product of the GUS protein in the soybean is measured. In addition, the transformation of pEIF1 and pEIF1-I driven GUS protein in transformation of arabidopsis thaliana and tobacco is also realized.

The invention relates to an ionic liquid catalyst for synthesizing bio-based polycarbonate and a method for synthesizing the bio-based polycarbonate. According to the invention, the anion of the ionicliquid catalyst is an amino acid anion, and the cation of the ionic liquid catalyst is any one selected from the group consisting of a quaternary ammonium cation, a quaternary phosphine cation, an imidazole cation, a pyridine cation and a piperidine cation. The amino acid ionic liquid catalyst disclosed by the invention has the advantages of environmental friendliness, biodegradability and low residue; furthermore, the catalyst disclosed by the invention is excellent in catalytic performance; compared with traditional catalysts such as an alkali metal salt, an alkaline earth metal salt, a quaternary ammonium salt, a quaternary phosphonium salt or the like, inter-molecular hydrogen bonds formed by ionic liquid and isosorbide can break intramolecular hydrogen bonds formed by internal hydroxyl groups of the isosorbide, and a ratio of the internal hydroxyl groups to the external hydroxyl groups of the activated isosorbide is smaller than 1, so the bio-based polycarbonate with good thermalstability (wherein Tg = 174 DEG C) and high molecular weight is synthesized.

The invention relates to 5-cyclopropane spirocyclic hydantoin derivates with a structural formula, whereinR1 in the formula represents hydrogen, alkyl group, benz or substituted benz. The preparation method comprises: reacting 1-carboxyl-2, 2-dimethyl carbethoxycyclopropane with ethyl chloroformate, generating 1-acid azide-2, 2- dimethyl carbethoxycyclopropane under the action of NaN3; generating corresponding isocyanate by curtius rearing 1-acid azide-2, 2- dimethyl carbethoxycyclopropane, wherein the isocyanate is reacted with primary amine, secondary amine or ammonia water to obtain N-substituted ureido cyclopropane which closes loop to generate 5-cyclopropane spirocyclic hydantoin derivates. The preparation method of the invention is simple, the yield is high, and 5-cyclopropane spirocyclic hydantoin derivates can be easy to prepare. The compounds of the invention have good anticonvulsant activity.

The invention provides a method for regenerating catalysts for an olefin esterification reaction and a hydration reaction. Polymer adsorbed at the active center positions of the surfaces of the catalysts is leached and washed through organic solvents, the organic solvents for leaching is washed through distilled water, and the adsorbed water is removed through drying. The obtained regenerated catalysts can replace new catalysts to be supplemented to the olefin esterification reaction and the hydration reaction, and the indexes, including the activity, the particle size, the strength and the like, of the regenerated catalysts and the new catalysts are all the same.

The pharmaceutical application of a hesperetin derivative relates to the application thereof in the preparation of anti-inflammatory immune medicaments, in particular to the application in treatment of autoimmune diseases such as rheumatic, rheumatoid arthritis and osteoarthritis, and the like. The hesperetin derivative is the derivative which is prepared by a non-carbohydrate compound obtained by hydrolyzing hesperidin and removing glycosyl. The pharmacological effect of the hesperetin derivative is significantly higher than that of the parent hesperidin; and compared with traditional non-steroidal anti-inflammatory medicament naproxen and a medicament tripterygium treating rheumatoid arthritis, the hesperetin derivative has equivalent activeness, is safe and non-toxic, not only treats the symptom, but also treats the root, thus having very good medicinal prospect.

The invention discloses a preparation method of a hydrodemetalization catalyst for residuum. The method comprises the following process: first impregnating an alumina carrier with a polyethylene glycol solution with the mass fraction of 20%-70%; then drying the impregnated alumina carrier; and finally loading an active component onto the alumina carrier, and drying and roasting to obtain the hydrodemetalization catalyst. The hydrodemetalization catalyst prepared by the method has activity similar to that of the catalyst of the prior art, and reduces the amount of active component and the cost of production.

The invention discloses camphoryl thiosemicarbazones, and a preparation method and an anti-tumor activity study thereof. With camphor as a raw material and under an alkaline catalysis condition, a series of alpha,beta-unsaturated ketones are obtained through aldol condensation reaction of camphor with different aromatic aldehydes respectively, then a series of camphoryl thiosemicarbazones are obtained through condensation of alpha,beta-unsaturated ketones with thiosemicarbazide through catalysis of concentrated hydrochloric acid, and the anti-tumor activity of all the target products is studied. Experiments show that the camphoryl thiosemicarbazones have good inhibitory activity on human multiple myeloma cells (RPMI-8226), human breast cancer cells (MDA-MB-231) and human non-small cell lung cancer cells (A549), have less toxicity on normal cell human gastric mucosa cells (GES-1), thereby having potential anti-tumor application value.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of soybean gene promoters pRPS28 and pRPS28-I in soybeans, arabidopsis thaliana and tobaccos. According to the invention, a gene RPS28 and a gene EIF1 are cloned from soybeans; a promoter pRPS28 and a promoter pRPS28-I are obtained through a CTAB method, then a soybean stable transformation vector is constructed, expression of GUS protein driven by the pRPS28 and the pRPS28-I in all stages of soybean genetic transformation is achieved, it is found that the GUS driven by the pRPS28 and the pRPS28-I is expressed in cotyledons, radicles, germs, true leaves, compound leaves, buds, petioles, internodes, roots and root nodules, it is indicated that the pRPS28 and the pRPS28-I are pan-expression promoters, and the activity of the expression product of the GUS protein in the soybean is measured. In addition, the transformation of the GUS protein driven by the pRPS28 and the pRPS28-I in the transformation of the arabidopsis thaliana and the tobacco is also realized.

The invention provides an application of an isodaphnetin compound in the preparation of antidiabetic medicines. The structural formula of isodaphnetin is shown in the specification. According to the invention, a high-sugar high-fat forage combined with a small dosage of streptozotocin (STZ) is applied to establish type 2 diabetes rat models, and male SD adult rats can be fed with the high-sugar high-fat forage for 1 month to induce insulin resistances and injected with a small dosage of the STZ 25mg each kilogram in an abdominal cavity mode to establish the type 2 diabetes rat models; and said given medicine is injected in the abdominal cavity mode, and blood sugar, serum insulin, glucagon, mental states, body weights, water drinking amounts, appetites and the like of the rates are detection indexes. Experiment results show that after treating with isodaphnetin, the blood sugar values and the serum insulin levels of the type 2 diabetes rat models are obviously decreased (P is less than 0.01), and there are no obvious blood sugar value differences among rats having obvious increased insulin levels (P is greater than 0.05). So, isodaphnetin can be used for preparing the antidiabetic medicines. The medicine is a medicinal composition comprising isodaphnetin as an active compound and a medicinal carrier.

The invention relates to an ionic liquid catalyst for synthesizing bio-based polycarbonate and a method for synthesizing the bio-based polycarbonate. According to the invention, the anion of the ionicliquid catalyst is an amino acid anion, and the cation of the ionic liquid catalyst is any one selected from the group consisting of a quaternary ammonium cation, a quaternary phosphine cation, an imidazole cation, a pyridine cation and a piperidine cation. The amino acid ionic liquid catalyst disclosed by the invention has the advantages of environmental friendliness, biodegradability and low residue; furthermore, the catalyst disclosed by the invention is excellent in catalytic performance; compared with traditional catalysts such as an alkali metal salt, an alkaline earth metal salt, a quaternary ammonium salt, a quaternary phosphonium salt or the like, inter-molecular hydrogen bonds formed by ionic liquid and isosorbide can break intramolecular hydrogen bonds formed by internal hydroxyl groups of the isosorbide, and a ratio of the internal hydroxyl groups to the external hydroxyl groups of the activated isosorbide is smaller than 1, so the bio-based polycarbonate with good thermalstability (wherein Tg = 174 DEG C) and high molecular weight is synthesized.

The invention discloses a preparation method for a pre-reduction type copper-zinc-aluminum low-temperature shift catalyst. The preparation method comprises the following steps of putting the existingoxidizing type copper-zinc-aluminum low-temperature shift catalyst into a reduction furnace, and introducing reductive gas into the reduction furnace to perform reduction reaction on the catalyst; when the catalyst is completely reduced in the reduction furnace introducing a stabilizer into the reduction furnace to react with the catalyst; packaging the copper-zinc-aluminum low-temperature shift catalyst in the reduction furnace under the protection environment of non-oxidizing gas. The preparation method has the advantages that the pre-reduction type is adopted for the copper-zinc-aluminum low-temperature shift catalyst, and the re-reduction is not needed before the catalyst is used for a factory; the activity of the catalyst is equivalent to the activity of the market industrial low-temperature shift catalyst after reduction, so that a large amount of production time of the factory is shortened, and a large amount of reduction cost of the factory is reduced; the reduction step of thefactory is not needed, and the temperature runaway due to false operation in the reduction process of the factory is avoided.

The invention relates to working place amplified microbiological product and its preparation manufacturing method. It includes microorganism bacteria species and nutrient. And their weight ratio is 1:5-1:500. The microorganism preparation can be formed by adding water, controlling temperature, and natural fermenting for the microbiological product. The invention can adjust the production according to actual demand, and make the preparation be used at the salad days. Meanwhile it realizes í‹zero package, zero transportation, and zero linkíŒ to make preparation manufacturing and using cost reduce, and make it be good for user using.

The present invention provides an isolated monoclonal antibody that specifically binds human TIM-3. The present invention further provides a pharmaceutical composition comprising the antibody, as wellas uses thereof. The invention further provides immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies, as well as diagnostic and therapeutic methods of using the anti-TIM-3 antibodies of the invention.

The invention discloses a shell-based nitrogen-doped activated carbon catalyst prepared by a one-step method. The method comprises the following steps: 1) preprocessing shells; 2) dipping shells in adipping solution containing a nitrogen source to obtain a catalyst precursor; and 3) carbonizing the catalyst precursor under the protection of inert gas to obtain the nitrogen-doped activated carboncatalyst. Compared with a preparation method taking activated carbon as a carrier, the preparation method takes shells (activated carbon precursor) as the carrier, the preparation process is more simplified, the production cost is greatly reduced, and the method is more energy-saving and environment-friendly. Compared with an organic micromolecular nitrogen-containing compound, amino resin has higher thermal stability, a catalyst with equivalent activity can be obtained under the condition of lower loading capacity, and the cost of raw materials is effectively saved.

The invention discloses a camphoryl thiosemicarbazone compound, a preparation method thereof and research on antitumor activity. The present invention uses camphor as a raw material, under alkaline catalytic conditions, carries out aldol condensation reaction with different aromatic aldehydes respectively to obtain a series of α, β-unsaturated ketones, and then catalyzes with concentrated hydrochloric acid, and condenses with thiosemicarbazide to obtain a series of camphor Based on thiosemicarbazone compounds, and the anti-tumor activity of all target products were studied. Experiments have shown that camphor-based thiosemicarbazone compounds have good inhibitory effects on human multiple myeloma cells (RPMI‑8226), human breast cancer cells (MDA‑MB‑231) and human non-small cell lung cancer cells (A549). activity, and has less toxicity to normal human gastric mucosal cells (GES-1), so it has potential anti-tumor application value.

The present invention relates to a novel purpose of hederagenin and a derivative of the hederagenin. An anti-depression test of the hederagenin and the derivative of the hederagenin shows obvious anti-depression activity, wherein, the salt derivative of the hederagenin has stronger anti-depression activity than the hederagenin; the hederagenin has stronger anti-depression activity than hederangenoside; the activities of the hederagenin and a hypericum extract are equivalent; sodium hederagenin has higher activity than the hypericum extract. The present invention has obvious pharmacological effect and stable quality; the raw material of the present invention has abundant source and cheap price and is safe with low toxin; the present invention has simple preparation technology and high yield, which provides novel medicine source for preventing, diagnosing, examining, protecting, remedying and researching on the depression and diseases directly related to the depression, is fit for the industrialization production, is easy for popularizing and applying and has very important value for developing and using Chinese officinal plant resource. Affective mental disorder is listed at top inChinese disease general burden, and the research and manufacture of the drug for preventing and remedying the depression has obvious social benefit and economic benefit.

The invention belongs to the technical field of plant genetic engineering, in particular to a soybean gene promoter pEIF1 and pEIF1‑I Application in soybean, Arabidopsis and tobacco. The present invention clones the gene from soybean RPS28 and genes EIF1 ; Get the promoter by CTAB method pEIF1 and promoter pEIF1‑I , and then construct a soybean stable transformation vector, and realize pEIF1 and pEIF1‑I The expression of the driven GUS protein at each stage of soybean genetic transformation, found that pEIF1 , pEIF1‑I The driven GUS is expressed in cotyledons, radicles, germs, true leaves, compound leaves, buds, petioles, internodes, roots and nodules, indicating that pEIF1 and pEIF1- I It is a ubiquitous expression promoter, and the activity of GUS protein expression product in soybean is determined. In addition, it also implements pEIF1 and pEIF1‑I Driving transformation of GUS proteins in Arabidopsis and tobacco transformation.

The invention discloses a preparation method for a pre-reduction type copper-zinc-aluminum low-temperature shift catalyst. The preparation method comprises the following steps of putting the existingoxidizing type copper-zinc-aluminum low-temperature shift catalyst into a reduction furnace, and introducing reductive gas into the reduction furnace to perform reduction reaction on the catalyst; when the catalyst is completely reduced in the reduction furnace introducing a stabilizer into the reduction furnace to react with the catalyst; packaging the copper-zinc-aluminum low-temperature shift catalyst in the reduction furnace under the protection environment of non-oxidizing gas. The preparation method has the advantages that the pre-reduction type is adopted for the copper-zinc-aluminum low-temperature shift catalyst, and the re-reduction is not needed before the catalyst is used for a factory; the activity of the catalyst is equivalent to the activity of the market industrial low-temperature shift catalyst after reduction, so that a large amount of production time of the factory is shortened, and a large amount of reduction cost of the factory is reduced; the reduction step of thefactory is not needed, and the temperature runaway due to false operation in the reduction process of the factory is avoided.

The invention relates to the field of biomedicine, in particular to the use of a class of Rakicidins compounds for resisting clinical pathogenic anaerobic bacteria. Pharmacodynamic experiments prove that the Rakicidins compounds have good efficacy against clinically pathogenic anaerobic bacteria, and have efficacy against diseases caused by vancomycin-resistant enterococcus infection. It can be used to treat diarrhea caused by Clostridium difficile, enteritis, digestive tract infection, oral infection or skin acne, urinary tract infection or skin and soft tissue infection and other diseases.

The invention provides an application of a saponin thorn counterfeit product in the preparation of antioxidants. After the detection of the antioxidant activity of the saponin thorn counterfeit product, compared with rutin, hawthorn extract and other substances, the saponin thorn counterfeit product has It shows comparable activity or even better activity. The DPPH free radical scavenging rate can reach 60%-75%, and the ORAC value can reach 1.20-1.30. It provides a new strategy for the research and development of related preparations and drugs, and has a good application prospects and high application value.

The present invention provides a kind of regeneration method that can make the palladium catalyst that can make the palladium catalyst that still can't meet the production requirement reach the activity required for production after the existing regeneration method treatment, comprises the following steps: Step 1: will need Impurity removal in the regenerated palladium catalyst; step 2: reacting the palladium catalyst after removing impurities with sodium chlorate solution and hydrochloric acid; step 3: adjusting the pH value of the solution after the reaction in step 2 to more than 4, and drying; step 4: The sample dried in step 3 is roasted.